<code id='3A17EA5196'></code><style id='3A17EA5196'></style>
    • <acronym id='3A17EA5196'></acronym>
      <center id='3A17EA5196'><center id='3A17EA5196'><tfoot id='3A17EA5196'></tfoot></center><abbr id='3A17EA5196'><dir id='3A17EA5196'><tfoot id='3A17EA5196'></tfoot><noframes id='3A17EA5196'>

    • <optgroup id='3A17EA5196'><strike id='3A17EA5196'><sup id='3A17EA5196'></sup></strike><code id='3A17EA5196'></code></optgroup>
        1. <b id='3A17EA5196'><label id='3A17EA5196'><select id='3A17EA5196'><dt id='3A17EA5196'><span id='3A17EA5196'></span></dt></select></label></b><u id='3A17EA5196'></u>
          <i id='3A17EA5196'><strike id='3A17EA5196'><tt id='3A17EA5196'><pre id='3A17EA5196'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:27
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Violet CEO on training clinicians to promote more inclusive care
          Violet CEO on training clinicians to promote more inclusive care

          GaurangChoksiisthefounderandCEOofViolet,ahealthequityplatform.CourtesyGaurangChoksiPHOENIX,Ariz.—Gau

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

          CraigF.Walker/TheBostonGlobeMaryBrownwassippingcoffeeathomeinOntario,Calif.,Sundaymorningwhenafriend